- Stifel notes 4Q EPS of $6.13 beat consensus ($5.99) on lower revenue ($27.7bn down 3% cc, consensus $28.0bn) and tax rate (11%). The lower tax rate contributed $0.62 to EPS, although IBM has always viewed the tax rate as an operational lever and telegraphed the lower rate. Core issues were continued weakness in the Growth Markets (GMU's down 6% versus -5% in September), China remained particularly weak (down 23% y/y), hardware was down 25% as expected due to the anniversary of the mainframe product cycle and known product transitions. Software grew in its target range (+4%); Services was consistent with 3Q, which was modestly below their expectations as cyclical and perhaps some customer specific issues continue to impact GTS growth.
- ISI notes the Dec-13 again highlighted challenges IBM is facing to revive its business (e.g., Software only up ~3% y/y, Services down y/y and systems down 26% y/y). In its view, the core of IBM's old playbook has been based primarily on: 1) large share buybacks, 2) highly disciplined expense management, 3) portfolio rationalization with a focus on services/software, and 4) tuck-in m&a. While this strategy historically produced consistent double-digit EPS growth, ISI believes a new strategy is required as large portions of IBM's highly profitable software/services business is under threat from SaaS and cloud migration. Maintaining relevance in large accounts will require bigger/bolder m&a in ISI's view, even if dilutive to EPS in the early years.
- RBC notes IBM was able to beat Street EPS expectations during the quarter largely due to a lower tax rate and share buyback benefits. RBC believes EPS guidance for FY14 is achievable and positions the firm well toward achieving its $20 EPS target by FY15.
Gapping down: AMD -11.3%, KERX -5.1%, NKTR -4.8%, IBKR -4.6%, BOBE -4.3%, XLNX -3.7%, IBM -3.4%, FNB -2.7%, NBG -2.6%, TEL -2.3%, ING -2.1%, SPLK -1.8%, AU -1.8%, VMW -1.6%, DB -1.5%, FE -1.4%, ONVO -1.2%, HPQ -1%, TXN -1%, JE -0.9%, MTW -0.9%, EMC -0.7%
+------------------------------------------------------------------------------+
Shire Has Scope for More M&A, Barclays Says 2014-01-22 10:24:01.314 GMT
By Sheela Sharma Jan. 22 (Bloomberg) -- Shire has scope for more M&A; expect additional corporate activity, most likely Rare Disease pipeline strengthening, to be announced during 2014, Barclays (overweight, PT 3,275p vs 2,800p previously) writes in note. * Acquisition of Viropharma limits size of future near-term deals, though with strong free cash flow generation (>$2b pa) this can be paid off within 2-3 yrs * Viropharma will add ~12% to 2015 EPS, divestment of loss- making Dermagraft adds 3%-5% to EPS; * Leaves stk on ~14x PE in 2015, 11% discount to mid-cap peers despite superior long-term EPS growth * Yday: JPMorgan said bolt-ons seen as main use of cash for EU large pharma; highlights Shire * Nov. 11: Shire announced plan to buy Viropharma for $50-shr * Jan. 17: Shire sells Dermagraft, sees impairement of ~$650m in 4Q * NOTE: Shire cash, near cash items at Sept. 30 was $1.7b: Bloomberg data
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editor: James Ludden
To contact the reporter on this story: Sheela Sharma in London at +44-20-7392-0395 or ssharma145@bloomberg.net
To contact the editor responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net
- Commerzbank says 4Q results, due Feb. 6, expected to be “rather subdued”
- While subscriber gains likely to accelerate due to shift of DT customers in 2H, this seems already taken fully into account
- Doesn’t see any positive catalysts for the stock in S/T
- Reiterates hold
- 12 buys, 9 holds, 7 sells; avg. PT EU7.6 implies upside of 5.7%: data compiled by Bloomberg
- Shares up as much as 0.7% today; down 10% since start of Jan., up 94% in 2014
- NOTE: Co. said Nov. 5 3Q Ebitda rose 19% to EU29.2m, said expects FY 2013 Ebitda to be positive, to grow strongly thereafter
- NOTE: Current estimates have 2014 Ebitda at EU116.7m:
+------------------------------------------------------------------------------+
Numericable Valuation Justified on Possible M&A Boost, Citi Says 2014-01-22 08:33:02.210 GMT
By Blanche Gatt Jan. 22 (Bloomberg) -- Numericable is “strategic asset” in a mkt that needs consolidation, Citi says in note; initiates coverage with neutral rating, PT EU29.5. * Citi says co.’s premium valuation at 10x est. 2014 EV/adj. Ebitda, 23.1x est. 2014 EV/OpFCF is justified given est. 60% probability of merger with SFR, with SFR spin-off in 1H as catalyst * Sees potential cost savings upside of EU2.8b, post integration costs, from any merger between SFR and Numericable * Says as standalone business Numericable offers limited growth with not much scope for price increases amid “fierce” competition * Shares up 0.8% today; up 10% since start of Jan., up 17% since IPO on Nov. 8 * Stock has 10 holds, 1 sell; avg. PT EU28.3 implies downside of 2.3%: data compiled by Bloomberg * NOTE Jan. 21: Vivendi Is Said to Explore Sale of SFR to Numericable Owner * Jan. 21: Vivendi’s Potential SFR Unit Sale Report Raises Hopes: Liberum
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editor: James Cone
To contact the reporter on this story: Blanche Gatt in London at +44-20-7392-0351 or bgatt@bloomberg.net
To contact the editor responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net
+------------------------------------------------------------------------------+
TF1 Likely to Pay Special Div. With Eurosport Proceeds: Goldman 2014-01-22 07:50:30.446 GMT
By Blanche Gatt Jan. 22 (Bloomberg) -- TF1 expected to use proceeds of sale of further 31% of Eurosport to Discovery, announced yday, for special div. to shareholders, Goldman Sachs says in note. * Goldman says proceeds, amounting to EU253m, would result in special div. of EU1.2/shr * Sale of 31% stake implies 10% dilutive effect on 2014 EPS est., Goldman says * Sees potential upside from French ad recovery, ameliorating competitive outlook, possibility of more cost savings, cash returns; reiterates buy * NOTE today: TF1 Gets Good Deal in Eurosport Control Sale to Discovery: JPM
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Blanche Gatt in London at +44-20-7392-0351 or bgatt@bloomberg.net
To contact the editor responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net